resource source identifier jr ab2 011 targetmol Search Results


jr ab2 011  (TargetMol)
93
TargetMol jr ab2 011
Jr Ab2 011, supplied by TargetMol, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/jr ab2 011/product/TargetMol
Average 93 stars, based on 1 article reviews
jr ab2 011 - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier
s1039 jr ab2 011 targetmol  (Selleck Chemicals)
96
Selleck Chemicals s1039 jr ab2 011 targetmol
S1039 Jr Ab2 011 Targetmol, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/s1039 jr ab2 011 targetmol/product/Selleck Chemicals
Average 96 stars, based on 1 article reviews
s1039 jr ab2 011 targetmol - by Bioz Stars, 2026-03
96/100 stars
  Buy from Supplier
everolimus targetmol 20 nmol l  (TargetMol)
93
TargetMol everolimus targetmol 20 nmol l
Everolimus Targetmol 20 Nmol L, supplied by TargetMol, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/everolimus targetmol 20 nmol l/product/TargetMol
Average 93 stars, based on 1 article reviews
everolimus targetmol 20 nmol l - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier
ku0063794  (TargetMol)
92
TargetMol ku0063794
Activation of mTORC1 signaling decreases the CXCR4 level in EpCAM CAR-T cells. A, Fold-changes in transcription level of chemokine receptor genes in EpCAM CAR-T cell compared with control T cells, n = 3 human donors. B, FACS analysis of the proportion of CXCR4 + cells in control T cells and CAR-T cells. n = 4 normal human donors. Paired two-tailed Student t test. C, FACS analysis of CXCR4 expression in control T cells, T cells cultured with IL2 (100 U/mL), T cells stimulated with CD3/CD28 antibody (data shown as mean ± SD; one-way ANOVA with Tukey multiple comparisons test). D, FACS analysis of CXCR4 expression in T cells modified with control empty vector and EpCAM CAR-T cells. (data shown as mean ± SD; unpaired two-tailed Student t test). E, Transwell analysis of the counts of the control T cells (unmodified T cells) and EpCAM CAR-T cells that migrated to the lower chamber in response to CXCL12 (100 ng/mL). “-CXCL12,” without CXCL12 in the lower chamber; “+CXCL12,” with CXCL12 in the lower chamber (data shown as mean ± SD; unpaired two-tailed Student t test). Data shown are representative of three independent experiments. F, GSEA suggesting that EpCAM CAR-T cells are significantly enriched for the expression of transcripts with functional annotations related to the mTOR signaling pathway compared with control T cells (Enrichment plot: mTOR signaling pathway). G and H, FACS analysis of the phosphorylation of mTOR ( G ) and ribosomal protein S6 ( H ) in EpCAM CAR-T cells and control T cells, n = 3 normal human donors, paired two-tailed Student t test. I, Immunoblot analysis of mTOR signaling components in control T cells and EpCAM CAR-T cells, n = 3 normal human donors. Data are representative of two experiments. J, Transcription level of CXCR4 in EpCAM CAR-T cells treated with DMSO, rapamycin, everolimus, temsirolimus, JR-AB2–011, and <t>KU0063794</t> for 24 hours, n = 3(data shown as mean ± SD ordinary one-way ANOVA with Tukey multiple comparison test). K, FACS analysis of the proportion of CXCR4 + EpCAM CAR-T cells treated with DMSO, rapamycin, everolimus, temsirolimus, JR-AB2–011, and KU0063794 for 24 hours, n = 3 (data shown as mean ± SD; ordinary one-way ANOVA with Tukey multiple comparison test). L, FACS analysis of the proportion of CXCR4 + EpCAM CAR-T cells treated with 0 nmol/L, 5 nmol/L, 10 nmol/L, 20 nmol/L, and 40 nmol/L rapamycin for 6 days. ( n = 3, data shown as mean + SD; unpaired two-tailed Student t test; *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001, ns, not significant).
Ku0063794, supplied by TargetMol, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ku0063794/product/TargetMol
Average 92 stars, based on 1 article reviews
ku0063794 - by Bioz Stars, 2026-03
92/100 stars
  Buy from Supplier
temsirolimus  (TargetMol)
91
TargetMol temsirolimus
Activation of mTORC1 signaling decreases the CXCR4 level in EpCAM CAR-T cells. A, Fold-changes in transcription level of chemokine receptor genes in EpCAM CAR-T cell compared with control T cells, n = 3 human donors. B, FACS analysis of the proportion of CXCR4 + cells in control T cells and CAR-T cells. n = 4 normal human donors. Paired two-tailed Student t test. C, FACS analysis of CXCR4 expression in control T cells, T cells cultured with IL2 (100 U/mL), T cells stimulated with CD3/CD28 antibody (data shown as mean ± SD; one-way ANOVA with Tukey multiple comparisons test). D, FACS analysis of CXCR4 expression in T cells modified with control empty vector and EpCAM CAR-T cells. (data shown as mean ± SD; unpaired two-tailed Student t test). E, Transwell analysis of the counts of the control T cells (unmodified T cells) and EpCAM CAR-T cells that migrated to the lower chamber in response to CXCL12 (100 ng/mL). “-CXCL12,” without CXCL12 in the lower chamber; “+CXCL12,” with CXCL12 in the lower chamber (data shown as mean ± SD; unpaired two-tailed Student t test). Data shown are representative of three independent experiments. F, GSEA suggesting that EpCAM CAR-T cells are significantly enriched for the expression of transcripts with functional annotations related to the mTOR signaling pathway compared with control T cells (Enrichment plot: mTOR signaling pathway). G and H, FACS analysis of the phosphorylation of mTOR ( G ) and ribosomal protein S6 ( H ) in EpCAM CAR-T cells and control T cells, n = 3 normal human donors, paired two-tailed Student t test. I, Immunoblot analysis of mTOR signaling components in control T cells and EpCAM CAR-T cells, n = 3 normal human donors. Data are representative of two experiments. J, Transcription level of CXCR4 in EpCAM CAR-T cells treated with DMSO, rapamycin, everolimus, <t>temsirolimus,</t> JR-AB2–011, and KU0063794 for 24 hours, n = 3(data shown as mean ± SD ordinary one-way ANOVA with Tukey multiple comparison test). K, FACS analysis of the proportion of CXCR4 + EpCAM CAR-T cells treated with DMSO, rapamycin, everolimus, temsirolimus, JR-AB2–011, and KU0063794 for 24 hours, n = 3 (data shown as mean ± SD; ordinary one-way ANOVA with Tukey multiple comparison test). L, FACS analysis of the proportion of CXCR4 + EpCAM CAR-T cells treated with 0 nmol/L, 5 nmol/L, 10 nmol/L, 20 nmol/L, and 40 nmol/L rapamycin for 6 days. ( n = 3, data shown as mean + SD; unpaired two-tailed Student t test; *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001, ns, not significant).
Temsirolimus, supplied by TargetMol, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/temsirolimus/product/TargetMol
Average 91 stars, based on 1 article reviews
temsirolimus - by Bioz Stars, 2026-03
91/100 stars
  Buy from Supplier
rapamycin  (TargetMol)
99
TargetMol rapamycin
Activation of mTORC1 signaling decreases the CXCR4 level in EpCAM CAR-T cells. A, Fold-changes in transcription level of chemokine receptor genes in EpCAM CAR-T cell compared with control T cells, n = 3 human donors. B, FACS analysis of the proportion of CXCR4 + cells in control T cells and CAR-T cells. n = 4 normal human donors. Paired two-tailed Student t test. C, FACS analysis of CXCR4 expression in control T cells, T cells cultured with IL2 (100 U/mL), T cells stimulated with CD3/CD28 antibody (data shown as mean ± SD; one-way ANOVA with Tukey multiple comparisons test). D, FACS analysis of CXCR4 expression in T cells modified with control empty vector and EpCAM CAR-T cells. (data shown as mean ± SD; unpaired two-tailed Student t test). E, Transwell analysis of the counts of the control T cells (unmodified T cells) and EpCAM CAR-T cells that migrated to the lower chamber in response to CXCL12 (100 ng/mL). “-CXCL12,” without CXCL12 in the lower chamber; “+CXCL12,” with CXCL12 in the lower chamber (data shown as mean ± SD; unpaired two-tailed Student t test). Data shown are representative of three independent experiments. F, GSEA suggesting that EpCAM CAR-T cells are significantly enriched for the expression of transcripts with functional annotations related to the mTOR signaling pathway compared with control T cells (Enrichment plot: mTOR signaling pathway). G and H, FACS analysis of the phosphorylation of mTOR ( G ) and ribosomal protein S6 ( H ) in EpCAM CAR-T cells and control T cells, n = 3 normal human donors, paired two-tailed Student t test. I, Immunoblot analysis of mTOR signaling components in control T cells and EpCAM CAR-T cells, n = 3 normal human donors. Data are representative of two experiments. J, Transcription level of CXCR4 in EpCAM CAR-T cells treated with DMSO, rapamycin, everolimus, <t>temsirolimus,</t> JR-AB2–011, and KU0063794 for 24 hours, n = 3(data shown as mean ± SD ordinary one-way ANOVA with Tukey multiple comparison test). K, FACS analysis of the proportion of CXCR4 + EpCAM CAR-T cells treated with DMSO, rapamycin, everolimus, temsirolimus, JR-AB2–011, and KU0063794 for 24 hours, n = 3 (data shown as mean ± SD; ordinary one-way ANOVA with Tukey multiple comparison test). L, FACS analysis of the proportion of CXCR4 + EpCAM CAR-T cells treated with 0 nmol/L, 5 nmol/L, 10 nmol/L, 20 nmol/L, and 40 nmol/L rapamycin for 6 days. ( n = 3, data shown as mean + SD; unpaired two-tailed Student t test; *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001, ns, not significant).
Rapamycin, supplied by TargetMol, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rapamycin/product/TargetMol
Average 99 stars, based on 1 article reviews
rapamycin - by Bioz Stars, 2026-03
99/100 stars
  Buy from Supplier
pp2  (Selleck Chemicals)
95
Selleck Chemicals pp2
Activation of mTORC1 signaling decreases the CXCR4 level in EpCAM CAR-T cells. A, Fold-changes in transcription level of chemokine receptor genes in EpCAM CAR-T cell compared with control T cells, n = 3 human donors. B, FACS analysis of the proportion of CXCR4 + cells in control T cells and CAR-T cells. n = 4 normal human donors. Paired two-tailed Student t test. C, FACS analysis of CXCR4 expression in control T cells, T cells cultured with IL2 (100 U/mL), T cells stimulated with CD3/CD28 antibody (data shown as mean ± SD; one-way ANOVA with Tukey multiple comparisons test). D, FACS analysis of CXCR4 expression in T cells modified with control empty vector and EpCAM CAR-T cells. (data shown as mean ± SD; unpaired two-tailed Student t test). E, Transwell analysis of the counts of the control T cells (unmodified T cells) and EpCAM CAR-T cells that migrated to the lower chamber in response to CXCL12 (100 ng/mL). “-CXCL12,” without CXCL12 in the lower chamber; “+CXCL12,” with CXCL12 in the lower chamber (data shown as mean ± SD; unpaired two-tailed Student t test). Data shown are representative of three independent experiments. F, GSEA suggesting that EpCAM CAR-T cells are significantly enriched for the expression of transcripts with functional annotations related to the mTOR signaling pathway compared with control T cells (Enrichment plot: mTOR signaling pathway). G and H, FACS analysis of the phosphorylation of mTOR ( G ) and ribosomal protein S6 ( H ) in EpCAM CAR-T cells and control T cells, n = 3 normal human donors, paired two-tailed Student t test. I, Immunoblot analysis of mTOR signaling components in control T cells and EpCAM CAR-T cells, n = 3 normal human donors. Data are representative of two experiments. J, Transcription level of CXCR4 in EpCAM CAR-T cells treated with DMSO, rapamycin, everolimus, <t>temsirolimus,</t> JR-AB2–011, and KU0063794 for 24 hours, n = 3(data shown as mean ± SD ordinary one-way ANOVA with Tukey multiple comparison test). K, FACS analysis of the proportion of CXCR4 + EpCAM CAR-T cells treated with DMSO, rapamycin, everolimus, temsirolimus, JR-AB2–011, and KU0063794 for 24 hours, n = 3 (data shown as mean ± SD; ordinary one-way ANOVA with Tukey multiple comparison test). L, FACS analysis of the proportion of CXCR4 + EpCAM CAR-T cells treated with 0 nmol/L, 5 nmol/L, 10 nmol/L, 20 nmol/L, and 40 nmol/L rapamycin for 6 days. ( n = 3, data shown as mean + SD; unpaired two-tailed Student t test; *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001, ns, not significant).
Pp2, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pp2/product/Selleck Chemicals
Average 95 stars, based on 1 article reviews
pp2 - by Bioz Stars, 2026-03
95/100 stars
  Buy from Supplier
pf431396  (Selleck Chemicals)
93
Selleck Chemicals pf431396
Activation of mTORC1 signaling decreases the CXCR4 level in EpCAM CAR-T cells. A, Fold-changes in transcription level of chemokine receptor genes in EpCAM CAR-T cell compared with control T cells, n = 3 human donors. B, FACS analysis of the proportion of CXCR4 + cells in control T cells and CAR-T cells. n = 4 normal human donors. Paired two-tailed Student t test. C, FACS analysis of CXCR4 expression in control T cells, T cells cultured with IL2 (100 U/mL), T cells stimulated with CD3/CD28 antibody (data shown as mean ± SD; one-way ANOVA with Tukey multiple comparisons test). D, FACS analysis of CXCR4 expression in T cells modified with control empty vector and EpCAM CAR-T cells. (data shown as mean ± SD; unpaired two-tailed Student t test). E, Transwell analysis of the counts of the control T cells (unmodified T cells) and EpCAM CAR-T cells that migrated to the lower chamber in response to CXCL12 (100 ng/mL). “-CXCL12,” without CXCL12 in the lower chamber; “+CXCL12,” with CXCL12 in the lower chamber (data shown as mean ± SD; unpaired two-tailed Student t test). Data shown are representative of three independent experiments. F, GSEA suggesting that EpCAM CAR-T cells are significantly enriched for the expression of transcripts with functional annotations related to the mTOR signaling pathway compared with control T cells (Enrichment plot: mTOR signaling pathway). G and H, FACS analysis of the phosphorylation of mTOR ( G ) and ribosomal protein S6 ( H ) in EpCAM CAR-T cells and control T cells, n = 3 normal human donors, paired two-tailed Student t test. I, Immunoblot analysis of mTOR signaling components in control T cells and EpCAM CAR-T cells, n = 3 normal human donors. Data are representative of two experiments. J, Transcription level of CXCR4 in EpCAM CAR-T cells treated with DMSO, rapamycin, everolimus, <t>temsirolimus,</t> JR-AB2–011, and KU0063794 for 24 hours, n = 3(data shown as mean ± SD ordinary one-way ANOVA with Tukey multiple comparison test). K, FACS analysis of the proportion of CXCR4 + EpCAM CAR-T cells treated with DMSO, rapamycin, everolimus, temsirolimus, JR-AB2–011, and KU0063794 for 24 hours, n = 3 (data shown as mean ± SD; ordinary one-way ANOVA with Tukey multiple comparison test). L, FACS analysis of the proportion of CXCR4 + EpCAM CAR-T cells treated with 0 nmol/L, 5 nmol/L, 10 nmol/L, 20 nmol/L, and 40 nmol/L rapamycin for 6 days. ( n = 3, data shown as mean + SD; unpaired two-tailed Student t test; *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001, ns, not significant).
Pf431396, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pf431396/product/Selleck Chemicals
Average 93 stars, based on 1 article reviews
pf431396 - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier
pf562271  (Selleck Chemicals)
94
Selleck Chemicals pf562271
Activation of mTORC1 signaling decreases the CXCR4 level in EpCAM CAR-T cells. A, Fold-changes in transcription level of chemokine receptor genes in EpCAM CAR-T cell compared with control T cells, n = 3 human donors. B, FACS analysis of the proportion of CXCR4 + cells in control T cells and CAR-T cells. n = 4 normal human donors. Paired two-tailed Student t test. C, FACS analysis of CXCR4 expression in control T cells, T cells cultured with IL2 (100 U/mL), T cells stimulated with CD3/CD28 antibody (data shown as mean ± SD; one-way ANOVA with Tukey multiple comparisons test). D, FACS analysis of CXCR4 expression in T cells modified with control empty vector and EpCAM CAR-T cells. (data shown as mean ± SD; unpaired two-tailed Student t test). E, Transwell analysis of the counts of the control T cells (unmodified T cells) and EpCAM CAR-T cells that migrated to the lower chamber in response to CXCL12 (100 ng/mL). “-CXCL12,” without CXCL12 in the lower chamber; “+CXCL12,” with CXCL12 in the lower chamber (data shown as mean ± SD; unpaired two-tailed Student t test). Data shown are representative of three independent experiments. F, GSEA suggesting that EpCAM CAR-T cells are significantly enriched for the expression of transcripts with functional annotations related to the mTOR signaling pathway compared with control T cells (Enrichment plot: mTOR signaling pathway). G and H, FACS analysis of the phosphorylation of mTOR ( G ) and ribosomal protein S6 ( H ) in EpCAM CAR-T cells and control T cells, n = 3 normal human donors, paired two-tailed Student t test. I, Immunoblot analysis of mTOR signaling components in control T cells and EpCAM CAR-T cells, n = 3 normal human donors. Data are representative of two experiments. J, Transcription level of CXCR4 in EpCAM CAR-T cells treated with DMSO, rapamycin, everolimus, <t>temsirolimus,</t> JR-AB2–011, and KU0063794 for 24 hours, n = 3(data shown as mean ± SD ordinary one-way ANOVA with Tukey multiple comparison test). K, FACS analysis of the proportion of CXCR4 + EpCAM CAR-T cells treated with DMSO, rapamycin, everolimus, temsirolimus, JR-AB2–011, and KU0063794 for 24 hours, n = 3 (data shown as mean ± SD; ordinary one-way ANOVA with Tukey multiple comparison test). L, FACS analysis of the proportion of CXCR4 + EpCAM CAR-T cells treated with 0 nmol/L, 5 nmol/L, 10 nmol/L, 20 nmol/L, and 40 nmol/L rapamycin for 6 days. ( n = 3, data shown as mean + SD; unpaired two-tailed Student t test; *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001, ns, not significant).
Pf562271, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pf562271/product/Selleck Chemicals
Average 94 stars, based on 1 article reviews
pf562271 - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier
bkm120  (Selleck Chemicals)
94
Selleck Chemicals bkm120
Activation of mTORC1 signaling decreases the CXCR4 level in EpCAM CAR-T cells. A, Fold-changes in transcription level of chemokine receptor genes in EpCAM CAR-T cell compared with control T cells, n = 3 human donors. B, FACS analysis of the proportion of CXCR4 + cells in control T cells and CAR-T cells. n = 4 normal human donors. Paired two-tailed Student t test. C, FACS analysis of CXCR4 expression in control T cells, T cells cultured with IL2 (100 U/mL), T cells stimulated with CD3/CD28 antibody (data shown as mean ± SD; one-way ANOVA with Tukey multiple comparisons test). D, FACS analysis of CXCR4 expression in T cells modified with control empty vector and EpCAM CAR-T cells. (data shown as mean ± SD; unpaired two-tailed Student t test). E, Transwell analysis of the counts of the control T cells (unmodified T cells) and EpCAM CAR-T cells that migrated to the lower chamber in response to CXCL12 (100 ng/mL). “-CXCL12,” without CXCL12 in the lower chamber; “+CXCL12,” with CXCL12 in the lower chamber (data shown as mean ± SD; unpaired two-tailed Student t test). Data shown are representative of three independent experiments. F, GSEA suggesting that EpCAM CAR-T cells are significantly enriched for the expression of transcripts with functional annotations related to the mTOR signaling pathway compared with control T cells (Enrichment plot: mTOR signaling pathway). G and H, FACS analysis of the phosphorylation of mTOR ( G ) and ribosomal protein S6 ( H ) in EpCAM CAR-T cells and control T cells, n = 3 normal human donors, paired two-tailed Student t test. I, Immunoblot analysis of mTOR signaling components in control T cells and EpCAM CAR-T cells, n = 3 normal human donors. Data are representative of two experiments. J, Transcription level of CXCR4 in EpCAM CAR-T cells treated with DMSO, rapamycin, everolimus, <t>temsirolimus,</t> JR-AB2–011, and KU0063794 for 24 hours, n = 3(data shown as mean ± SD ordinary one-way ANOVA with Tukey multiple comparison test). K, FACS analysis of the proportion of CXCR4 + EpCAM CAR-T cells treated with DMSO, rapamycin, everolimus, temsirolimus, JR-AB2–011, and KU0063794 for 24 hours, n = 3 (data shown as mean ± SD; ordinary one-way ANOVA with Tukey multiple comparison test). L, FACS analysis of the proportion of CXCR4 + EpCAM CAR-T cells treated with 0 nmol/L, 5 nmol/L, 10 nmol/L, 20 nmol/L, and 40 nmol/L rapamycin for 6 days. ( n = 3, data shown as mean + SD; unpaired two-tailed Student t test; *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001, ns, not significant).
Bkm120, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/bkm120/product/Selleck Chemicals
Average 94 stars, based on 1 article reviews
bkm120 - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier
cftrinh 172  (Selleck Chemicals)
93
Selleck Chemicals cftrinh 172
Activation of mTORC1 signaling decreases the CXCR4 level in EpCAM CAR-T cells. A, Fold-changes in transcription level of chemokine receptor genes in EpCAM CAR-T cell compared with control T cells, n = 3 human donors. B, FACS analysis of the proportion of CXCR4 + cells in control T cells and CAR-T cells. n = 4 normal human donors. Paired two-tailed Student t test. C, FACS analysis of CXCR4 expression in control T cells, T cells cultured with IL2 (100 U/mL), T cells stimulated with CD3/CD28 antibody (data shown as mean ± SD; one-way ANOVA with Tukey multiple comparisons test). D, FACS analysis of CXCR4 expression in T cells modified with control empty vector and EpCAM CAR-T cells. (data shown as mean ± SD; unpaired two-tailed Student t test). E, Transwell analysis of the counts of the control T cells (unmodified T cells) and EpCAM CAR-T cells that migrated to the lower chamber in response to CXCL12 (100 ng/mL). “-CXCL12,” without CXCL12 in the lower chamber; “+CXCL12,” with CXCL12 in the lower chamber (data shown as mean ± SD; unpaired two-tailed Student t test). Data shown are representative of three independent experiments. F, GSEA suggesting that EpCAM CAR-T cells are significantly enriched for the expression of transcripts with functional annotations related to the mTOR signaling pathway compared with control T cells (Enrichment plot: mTOR signaling pathway). G and H, FACS analysis of the phosphorylation of mTOR ( G ) and ribosomal protein S6 ( H ) in EpCAM CAR-T cells and control T cells, n = 3 normal human donors, paired two-tailed Student t test. I, Immunoblot analysis of mTOR signaling components in control T cells and EpCAM CAR-T cells, n = 3 normal human donors. Data are representative of two experiments. J, Transcription level of CXCR4 in EpCAM CAR-T cells treated with DMSO, rapamycin, everolimus, <t>temsirolimus,</t> JR-AB2–011, and KU0063794 for 24 hours, n = 3(data shown as mean ± SD ordinary one-way ANOVA with Tukey multiple comparison test). K, FACS analysis of the proportion of CXCR4 + EpCAM CAR-T cells treated with DMSO, rapamycin, everolimus, temsirolimus, JR-AB2–011, and KU0063794 for 24 hours, n = 3 (data shown as mean ± SD; ordinary one-way ANOVA with Tukey multiple comparison test). L, FACS analysis of the proportion of CXCR4 + EpCAM CAR-T cells treated with 0 nmol/L, 5 nmol/L, 10 nmol/L, 20 nmol/L, and 40 nmol/L rapamycin for 6 days. ( n = 3, data shown as mean + SD; unpaired two-tailed Student t test; *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001, ns, not significant).
Cftrinh 172, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cftrinh 172/product/Selleck Chemicals
Average 93 stars, based on 1 article reviews
cftrinh 172 - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier
forskolin  (Cell Signaling Technology Inc)
95
Cell Signaling Technology Inc forskolin
Activation of mTORC1 signaling decreases the CXCR4 level in EpCAM CAR-T cells. A, Fold-changes in transcription level of chemokine receptor genes in EpCAM CAR-T cell compared with control T cells, n = 3 human donors. B, FACS analysis of the proportion of CXCR4 + cells in control T cells and CAR-T cells. n = 4 normal human donors. Paired two-tailed Student t test. C, FACS analysis of CXCR4 expression in control T cells, T cells cultured with IL2 (100 U/mL), T cells stimulated with CD3/CD28 antibody (data shown as mean ± SD; one-way ANOVA with Tukey multiple comparisons test). D, FACS analysis of CXCR4 expression in T cells modified with control empty vector and EpCAM CAR-T cells. (data shown as mean ± SD; unpaired two-tailed Student t test). E, Transwell analysis of the counts of the control T cells (unmodified T cells) and EpCAM CAR-T cells that migrated to the lower chamber in response to CXCL12 (100 ng/mL). “-CXCL12,” without CXCL12 in the lower chamber; “+CXCL12,” with CXCL12 in the lower chamber (data shown as mean ± SD; unpaired two-tailed Student t test). Data shown are representative of three independent experiments. F, GSEA suggesting that EpCAM CAR-T cells are significantly enriched for the expression of transcripts with functional annotations related to the mTOR signaling pathway compared with control T cells (Enrichment plot: mTOR signaling pathway). G and H, FACS analysis of the phosphorylation of mTOR ( G ) and ribosomal protein S6 ( H ) in EpCAM CAR-T cells and control T cells, n = 3 normal human donors, paired two-tailed Student t test. I, Immunoblot analysis of mTOR signaling components in control T cells and EpCAM CAR-T cells, n = 3 normal human donors. Data are representative of two experiments. J, Transcription level of CXCR4 in EpCAM CAR-T cells treated with DMSO, rapamycin, everolimus, <t>temsirolimus,</t> JR-AB2–011, and KU0063794 for 24 hours, n = 3(data shown as mean ± SD ordinary one-way ANOVA with Tukey multiple comparison test). K, FACS analysis of the proportion of CXCR4 + EpCAM CAR-T cells treated with DMSO, rapamycin, everolimus, temsirolimus, JR-AB2–011, and KU0063794 for 24 hours, n = 3 (data shown as mean ± SD; ordinary one-way ANOVA with Tukey multiple comparison test). L, FACS analysis of the proportion of CXCR4 + EpCAM CAR-T cells treated with 0 nmol/L, 5 nmol/L, 10 nmol/L, 20 nmol/L, and 40 nmol/L rapamycin for 6 days. ( n = 3, data shown as mean + SD; unpaired two-tailed Student t test; *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001, ns, not significant).
Forskolin, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/forskolin/product/Cell Signaling Technology Inc
Average 95 stars, based on 1 article reviews
forskolin - by Bioz Stars, 2026-03
95/100 stars
  Buy from Supplier

Image Search Results


Activation of mTORC1 signaling decreases the CXCR4 level in EpCAM CAR-T cells. A, Fold-changes in transcription level of chemokine receptor genes in EpCAM CAR-T cell compared with control T cells, n = 3 human donors. B, FACS analysis of the proportion of CXCR4 + cells in control T cells and CAR-T cells. n = 4 normal human donors. Paired two-tailed Student t test. C, FACS analysis of CXCR4 expression in control T cells, T cells cultured with IL2 (100 U/mL), T cells stimulated with CD3/CD28 antibody (data shown as mean ± SD; one-way ANOVA with Tukey multiple comparisons test). D, FACS analysis of CXCR4 expression in T cells modified with control empty vector and EpCAM CAR-T cells. (data shown as mean ± SD; unpaired two-tailed Student t test). E, Transwell analysis of the counts of the control T cells (unmodified T cells) and EpCAM CAR-T cells that migrated to the lower chamber in response to CXCL12 (100 ng/mL). “-CXCL12,” without CXCL12 in the lower chamber; “+CXCL12,” with CXCL12 in the lower chamber (data shown as mean ± SD; unpaired two-tailed Student t test). Data shown are representative of three independent experiments. F, GSEA suggesting that EpCAM CAR-T cells are significantly enriched for the expression of transcripts with functional annotations related to the mTOR signaling pathway compared with control T cells (Enrichment plot: mTOR signaling pathway). G and H, FACS analysis of the phosphorylation of mTOR ( G ) and ribosomal protein S6 ( H ) in EpCAM CAR-T cells and control T cells, n = 3 normal human donors, paired two-tailed Student t test. I, Immunoblot analysis of mTOR signaling components in control T cells and EpCAM CAR-T cells, n = 3 normal human donors. Data are representative of two experiments. J, Transcription level of CXCR4 in EpCAM CAR-T cells treated with DMSO, rapamycin, everolimus, temsirolimus, JR-AB2–011, and KU0063794 for 24 hours, n = 3(data shown as mean ± SD ordinary one-way ANOVA with Tukey multiple comparison test). K, FACS analysis of the proportion of CXCR4 + EpCAM CAR-T cells treated with DMSO, rapamycin, everolimus, temsirolimus, JR-AB2–011, and KU0063794 for 24 hours, n = 3 (data shown as mean ± SD; ordinary one-way ANOVA with Tukey multiple comparison test). L, FACS analysis of the proportion of CXCR4 + EpCAM CAR-T cells treated with 0 nmol/L, 5 nmol/L, 10 nmol/L, 20 nmol/L, and 40 nmol/L rapamycin for 6 days. ( n = 3, data shown as mean + SD; unpaired two-tailed Student t test; *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001, ns, not significant).

Journal: Clinical Cancer Research

Article Title: Rapamycin Pretreatment Rescues the Bone Marrow AML Cell Elimination Capacity of CAR-T Cells

doi: 10.1158/1078-0432.CCR-21-0452

Figure Lengend Snippet: Activation of mTORC1 signaling decreases the CXCR4 level in EpCAM CAR-T cells. A, Fold-changes in transcription level of chemokine receptor genes in EpCAM CAR-T cell compared with control T cells, n = 3 human donors. B, FACS analysis of the proportion of CXCR4 + cells in control T cells and CAR-T cells. n = 4 normal human donors. Paired two-tailed Student t test. C, FACS analysis of CXCR4 expression in control T cells, T cells cultured with IL2 (100 U/mL), T cells stimulated with CD3/CD28 antibody (data shown as mean ± SD; one-way ANOVA with Tukey multiple comparisons test). D, FACS analysis of CXCR4 expression in T cells modified with control empty vector and EpCAM CAR-T cells. (data shown as mean ± SD; unpaired two-tailed Student t test). E, Transwell analysis of the counts of the control T cells (unmodified T cells) and EpCAM CAR-T cells that migrated to the lower chamber in response to CXCL12 (100 ng/mL). “-CXCL12,” without CXCL12 in the lower chamber; “+CXCL12,” with CXCL12 in the lower chamber (data shown as mean ± SD; unpaired two-tailed Student t test). Data shown are representative of three independent experiments. F, GSEA suggesting that EpCAM CAR-T cells are significantly enriched for the expression of transcripts with functional annotations related to the mTOR signaling pathway compared with control T cells (Enrichment plot: mTOR signaling pathway). G and H, FACS analysis of the phosphorylation of mTOR ( G ) and ribosomal protein S6 ( H ) in EpCAM CAR-T cells and control T cells, n = 3 normal human donors, paired two-tailed Student t test. I, Immunoblot analysis of mTOR signaling components in control T cells and EpCAM CAR-T cells, n = 3 normal human donors. Data are representative of two experiments. J, Transcription level of CXCR4 in EpCAM CAR-T cells treated with DMSO, rapamycin, everolimus, temsirolimus, JR-AB2–011, and KU0063794 for 24 hours, n = 3(data shown as mean ± SD ordinary one-way ANOVA with Tukey multiple comparison test). K, FACS analysis of the proportion of CXCR4 + EpCAM CAR-T cells treated with DMSO, rapamycin, everolimus, temsirolimus, JR-AB2–011, and KU0063794 for 24 hours, n = 3 (data shown as mean ± SD; ordinary one-way ANOVA with Tukey multiple comparison test). L, FACS analysis of the proportion of CXCR4 + EpCAM CAR-T cells treated with 0 nmol/L, 5 nmol/L, 10 nmol/L, 20 nmol/L, and 40 nmol/L rapamycin for 6 days. ( n = 3, data shown as mean + SD; unpaired two-tailed Student t test; *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001, ns, not significant).

Article Snippet: The medium was changed after 6–8 hours and rapamycin (Sigma) was added at a final concentration of 20 nmol/L, everolimus (TargetMol, 20 nmol/L), temsirolimus (TargetMol, 20 nmol/L), JR-AB2–011 (TargetMol, 1μmol/L), KU0063794 (TargetMol, 20 nmol/L); Rapamycin was supplemented every 2 days.

Techniques: Activation Assay, Control, Two Tailed Test, Expressing, Cell Culture, Modification, Plasmid Preparation, Functional Assay, Western Blot, Comparison

Activation of mTORC1 signaling decreases the CXCR4 level in EpCAM CAR-T cells. A, Fold-changes in transcription level of chemokine receptor genes in EpCAM CAR-T cell compared with control T cells, n = 3 human donors. B, FACS analysis of the proportion of CXCR4 + cells in control T cells and CAR-T cells. n = 4 normal human donors. Paired two-tailed Student t test. C, FACS analysis of CXCR4 expression in control T cells, T cells cultured with IL2 (100 U/mL), T cells stimulated with CD3/CD28 antibody (data shown as mean ± SD; one-way ANOVA with Tukey multiple comparisons test). D, FACS analysis of CXCR4 expression in T cells modified with control empty vector and EpCAM CAR-T cells. (data shown as mean ± SD; unpaired two-tailed Student t test). E, Transwell analysis of the counts of the control T cells (unmodified T cells) and EpCAM CAR-T cells that migrated to the lower chamber in response to CXCL12 (100 ng/mL). “-CXCL12,” without CXCL12 in the lower chamber; “+CXCL12,” with CXCL12 in the lower chamber (data shown as mean ± SD; unpaired two-tailed Student t test). Data shown are representative of three independent experiments. F, GSEA suggesting that EpCAM CAR-T cells are significantly enriched for the expression of transcripts with functional annotations related to the mTOR signaling pathway compared with control T cells (Enrichment plot: mTOR signaling pathway). G and H, FACS analysis of the phosphorylation of mTOR ( G ) and ribosomal protein S6 ( H ) in EpCAM CAR-T cells and control T cells, n = 3 normal human donors, paired two-tailed Student t test. I, Immunoblot analysis of mTOR signaling components in control T cells and EpCAM CAR-T cells, n = 3 normal human donors. Data are representative of two experiments. J, Transcription level of CXCR4 in EpCAM CAR-T cells treated with DMSO, rapamycin, everolimus, temsirolimus, JR-AB2–011, and KU0063794 for 24 hours, n = 3(data shown as mean ± SD ordinary one-way ANOVA with Tukey multiple comparison test). K, FACS analysis of the proportion of CXCR4 + EpCAM CAR-T cells treated with DMSO, rapamycin, everolimus, temsirolimus, JR-AB2–011, and KU0063794 for 24 hours, n = 3 (data shown as mean ± SD; ordinary one-way ANOVA with Tukey multiple comparison test). L, FACS analysis of the proportion of CXCR4 + EpCAM CAR-T cells treated with 0 nmol/L, 5 nmol/L, 10 nmol/L, 20 nmol/L, and 40 nmol/L rapamycin for 6 days. ( n = 3, data shown as mean + SD; unpaired two-tailed Student t test; *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001, ns, not significant).

Journal: Clinical Cancer Research

Article Title: Rapamycin Pretreatment Rescues the Bone Marrow AML Cell Elimination Capacity of CAR-T Cells

doi: 10.1158/1078-0432.CCR-21-0452

Figure Lengend Snippet: Activation of mTORC1 signaling decreases the CXCR4 level in EpCAM CAR-T cells. A, Fold-changes in transcription level of chemokine receptor genes in EpCAM CAR-T cell compared with control T cells, n = 3 human donors. B, FACS analysis of the proportion of CXCR4 + cells in control T cells and CAR-T cells. n = 4 normal human donors. Paired two-tailed Student t test. C, FACS analysis of CXCR4 expression in control T cells, T cells cultured with IL2 (100 U/mL), T cells stimulated with CD3/CD28 antibody (data shown as mean ± SD; one-way ANOVA with Tukey multiple comparisons test). D, FACS analysis of CXCR4 expression in T cells modified with control empty vector and EpCAM CAR-T cells. (data shown as mean ± SD; unpaired two-tailed Student t test). E, Transwell analysis of the counts of the control T cells (unmodified T cells) and EpCAM CAR-T cells that migrated to the lower chamber in response to CXCL12 (100 ng/mL). “-CXCL12,” without CXCL12 in the lower chamber; “+CXCL12,” with CXCL12 in the lower chamber (data shown as mean ± SD; unpaired two-tailed Student t test). Data shown are representative of three independent experiments. F, GSEA suggesting that EpCAM CAR-T cells are significantly enriched for the expression of transcripts with functional annotations related to the mTOR signaling pathway compared with control T cells (Enrichment plot: mTOR signaling pathway). G and H, FACS analysis of the phosphorylation of mTOR ( G ) and ribosomal protein S6 ( H ) in EpCAM CAR-T cells and control T cells, n = 3 normal human donors, paired two-tailed Student t test. I, Immunoblot analysis of mTOR signaling components in control T cells and EpCAM CAR-T cells, n = 3 normal human donors. Data are representative of two experiments. J, Transcription level of CXCR4 in EpCAM CAR-T cells treated with DMSO, rapamycin, everolimus, temsirolimus, JR-AB2–011, and KU0063794 for 24 hours, n = 3(data shown as mean ± SD ordinary one-way ANOVA with Tukey multiple comparison test). K, FACS analysis of the proportion of CXCR4 + EpCAM CAR-T cells treated with DMSO, rapamycin, everolimus, temsirolimus, JR-AB2–011, and KU0063794 for 24 hours, n = 3 (data shown as mean ± SD; ordinary one-way ANOVA with Tukey multiple comparison test). L, FACS analysis of the proportion of CXCR4 + EpCAM CAR-T cells treated with 0 nmol/L, 5 nmol/L, 10 nmol/L, 20 nmol/L, and 40 nmol/L rapamycin for 6 days. ( n = 3, data shown as mean + SD; unpaired two-tailed Student t test; *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001, ns, not significant).

Article Snippet: The medium was changed after 6–8 hours and rapamycin (Sigma) was added at a final concentration of 20 nmol/L, everolimus (TargetMol, 20 nmol/L), temsirolimus (TargetMol, 20 nmol/L), JR-AB2–011 (TargetMol, 1μmol/L), KU0063794 (TargetMol, 20 nmol/L); Rapamycin was supplemented every 2 days.

Techniques: Activation Assay, Control, Two Tailed Test, Expressing, Cell Culture, Modification, Plasmid Preparation, Functional Assay, Western Blot, Comparison